Targets › PIK3D
1 program from 1 company in 2 trials: 2 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on PIK3D, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | Linperlisib PI3K inhibitor | PIK3CA, PIK3CB, PIK3D | Phase 2 | Relapsed/Refractory Large B-Cell Lymphoma; Lymphoma, T-Cell | Dec 2026 |
Relapsed/Refractory Large B-Cell Lymphoma (1) Lymphoma, T-Cell (1)
small molecule (1)
Institute of Hematology & Blood Diseases Hospital, China (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.